/
Oncology
Newly Diagnosed Multiple Myeloma
9
Pipeline Programs↗
5
Active Trials↗
4
Companies Involved↗
Newly Diagnosed Multiple Myeloma is an early-stage landscape with 9 programs across 4 companies. The most active players are AstraZeneca. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 38
Approved
No programs
Analysis
Modality Breakdown
7programs
Small molecule457%
Monoclonal antibody229%
Cell therapy114%
Modality classified for 78% of 9 pipeline programs.
Analysis
Trial Status
6
clinical trials
Not yet recruiting3 · 50%
Recruiting2 · 33%
Completed1 · 17%
Clinical Trials
Trial Activity
6 trials
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen, Consisting of Sodium Oxychloride, Caffizyme, Lenalidomide and Dexamethasone
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Approved·NCT07709884·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)